Five-year potency preservation after iodine-125 prostate brachytherapy.

Area of Science:

• Urology
• Oncology
• Men's Health

Background:

• Prostate brachytherapy is a common treatment for localized prostate cancer.
• Understanding long-term erectile function after brachytherapy is crucial for patient quality of life.

Purpose of the Study:

• To evaluate long-term erectile function following prostate brachytherapy.
• To identify patient characteristics and treatment factors influencing erectile function outcomes.

Main Methods:

• A cohort of 665 men with localized prostate cancer treated with Iodine-125 (125I) brachytherapy between 2003-2006 was analyzed.
• Erectile function was assessed using the Mount Sinai Erectile Function Score (MSEFS) pre-treatment and up to 5 years post-implantation.
• Univariate and multivariate analyses were performed on 382 potent pre-treatment patients to identify predictors of potency preservation.

Main Results:

• Actuarial potency preservation rates declined to 46.2% at 6 months post-brachytherapy, recovering to 52.0% at 5 years.
• Multivariate analysis identified patient age (p=0.04) and pre-treatment MSEFS (p<0.001) as significant predictors of 5-year potency preservation.
• Neoadjuvant hormone therapy impacted potency preservation only at the 6-month mark.

Conclusions:

• Patient age at the time of implantation and pre-treatment erectile function are key predictors of post-brachytherapy erectile dysfunction.
• These factors are essential for counseling patients regarding potential sexual side effects of prostate brachytherapy.